文献速递头颈外科

远处转移性头颈部鳞状细胞癌的免疫治疗使用与结局

Immunotherapy Utilization Outcomes in Distantly Metastatic Head and Neck Squamous Cell Carcinoma.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

基于美国国家癌症数据库(NCDB)2013至2020年5059例远处转移性头颈部鳞状细胞癌(mHNSCC)患者的队列研究显示,免疫治疗使用率从2013年的9.3%升至2020年的33.8%。化疗联合免疫治疗的中位生存期最长,为19.1个月(95%CI 17.0-21.5),优于单纯化疗的17.3个月(95%CI 16.6-18.3);多因素Cox分析显示,与单纯化疗相比,联合免疫治疗改善总生存(HR 0.81,95%CI 0.72-0.91),但单纯免疫治疗总生存更差(HR 1.25,95%CI 1.08-1.45)。

要点

  • 2013至2020年mHNSCC免疫治疗使用率由9.3%升至33.8%。
  • 化疗联合免疫治疗中位生存19.1个月,单纯化疗为17.3个月。
  • 下咽、口腔、喉癌联合免疫治疗改善总生存,口咽癌未见改善。

核心结论

  • 2013至2020年mHNSCC免疫治疗使用显著增加,尤其在学术中心。
  • 免疫治疗与下咽癌、口腔癌和喉癌患者总生存的适度改善相关,但与口咽癌患者总生存改善无关。

研究设计与样本

  • 大型人群队列研究,使用美国国家癌症数据库(NCDB)数据,该数据库收录美国1500余家医院治疗的患者。
  • 纳入2013至2020年接受免疫治疗的mHNSCC患者,暴露为是否接受免疫治疗,主要结局为mHNSCC诊断后总生存(OS)。
  • 数据分析于2023年10月至2025年3月进行,采用Kaplan-Meier法和多因素Cox回归模型。

主要发现

  • 共纳入5059例mHNSCC患者,平均(SD)诊断年龄64.6(10.6)岁,男性4074例(80.5%),亚裔162例(3.2%)、黑人763例(15.1%)、西班牙裔267例(5.3%)、美洲原住民19例(0.4%)、白人3848例(76.1%)。
  • 1073例(21.3%)接受免疫治疗,3986例(78.8%)未接受;免疫治疗使用率从2013年的9.3%升至2020年的33.8%。
  • 免疫治疗接受者主要由Medicare覆盖(539例,22.3%)或私人保险覆盖(310例,23.9%)。
  • 化疗联合免疫治疗组中位生存期最长,为19.1个月(95%CI 17.0-21.5),单纯化疗组为17.3个月(95%CI 16.6-18.3)。
  • 多因素Cox分析显示,与单纯化疗相比,联合免疫治疗改善OS(HR 0.81,95%CI 0.72-0.91),单纯免疫治疗OS更差(HR 1.25,95%CI 1.08-1.45),未接受化疗或免疫治疗者OS更差(HR 2.31,95%CI 2.12-2.52)。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immunotherapy is part of multimodal treatment for distantly metastatic head and neck squamous cell carcinoma (mHNSCC); however, survival outcomes outside of clinical trials have not been systematically assessed. This study used the US National Cancer Database (NCDB) to evaluate the use and outcomes of nonpalliative immunotherapy across various HNSCC primary sites outside of clinical trial settings. OBJECTIVE: To assess the routine clinical use of nonpalliative immunotherapy and its survival outcomes for different primary sites of mHNSCC. DESIGN, SETTING, AND PARTICIPANTS: This was a large population-based cohort study using data from the NCDB, a cancer registry of patients treated at more than 1500 hospitals in the US. Eligible participants were patients with mHNSCC who received immunotherapy from 2013 to 2020. Data analysis was conducted from October 2023 and March 2025. EXPOSURE: Receiving immunotherapy or not. MAIN OUTCOMES AND MEASURES: Overall survival (OS) following mHNSCC diagnosis was the primary outcome. The secondary outcome was prognostic factors of OS stratified by primary site. Kaplan-Meier and multivariable Cox regression models were used in the analysis. RESULTS: Among 5059 patients with mHNSCC (mean [SD] age at diagnosis, 64.6 [10.6] years; 4074 male [80.5%]; 162 Asian [3.2%], 763 Black [15.1%], 267 Hispanic [5.3%], 19 Native American [0.4%], and 3848 White [76.1%] individuals), there were 1073 (21.3%) who received immunotherapy and 3986 (78.8%) who did not. Immunotherapy use increased year over year from 2013 to 2020 (9.3% vs 33.8%). Immunotherapy recipients were predominantly covered by Medicare (539 patients [22.3%]) or privately insured (310 patients [23.9%]). Patients receiving both chemotherapy and immunotherapy had the longest median survival at 19.1 (95% CI, 17.0-21.5) months, followed by those receiving chemotherapy alone at 17.3 (95% CI, 16.6-18.3) months. Compared to chemotherapy alone, multivariable Cox analysis demonstrated improved OS for the addition of immunotherapy (hazard ratio [HR], 0.81; 95% CI, 0.72-0.91) but worse OS for immunotherapy alone (HR, 1.25; 95% CI, 1.08-1.45) and no chemotherapy or immunotherapy (HR, 2.31; 95% CI, 2.12-2.52). Adding immunotherapy to chemotherapy improved OS in patients with hypopharyngeal (HR, 0.66; 95% CI, 0.50-0.86), oral cavity (HR, 0.76; 95% CI, 0.59-0.98), and laryngeal (HR, 0.81; 95% CI, 0.66-1.00) cancers, but not for p16-positive (HR, 1.05; 95% CI, 0.79-1.39) or p16-negative (HR, 1.33; 95% CI, 0.96-1.86) oropharyngeal cancers. CONCLUSIONS AND RELEVANCE: This cohort study found that immunotherapy use increased significantly from 2013 to 2020 for mHNSCC treatment, particularly at academic centers. Immunotherapy use was associated with modest OS improvement in patients with hypopharyngeal, oral cavity, and laryngeal cancers, but not for those with oropharyngeal cancer.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Sangal NR, Tapescu I, Kaki P, et al. Immunotherapy Utilization Outcomes in Distantly Metastatic Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40471563. doi:10.1001/jamaoto.2025.1351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。